A Phase 2 Dose Ranging, Randomized, Double Blind, Placebocontrolled Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of EDP-305 In Subjects With Primary Biliary Cholangitis (PBC) With Or Without An Inadequate Response To Ursodeoxycholic Acid (UDCA)
Principal Investigator (?)
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
Enanta Pharmaceuticals, Inc.
Available at the following location(s)